Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DDX3X | O00571 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4821983 | 0.98 | SYK (0.39) | SYKGRM5FPR2SLC22A12FPR3 | |
| SCHEMBL4670843 | 0.83 | SLC6A2 (0.37) | SYKFPR2FPR3LRRK2 | |
| SCHEMBL4670847 | 0.83 | TNF (0.38) | SYKLRRK2 | |
| SCHEMBL5302085 | 0.80 | KDM1A (0.30) | SYKFPR2 | |
| SCHEMBL4673438 | 0.79 | FPR2 (0.40) | GRM5FPR2FPR3HDAC1HDAC6 | |
| SCHEMBL4669074 | 0.77 | RAB9A (0.46) | — | |
| Fumaric Acid SCHEMBL4823389 | 0.73 | SYK (0.38) | SYKFPR2FPR3HDAC1HDAC8 | |
| SCHEMBL3632606 | 0.71 | ADRA2A (0.50) | SLC22A12HDAC1HDAC8HDAC6NPSR1 | |
| SCHEMBL6138308 | 0.71 | CHRNB1 (0.40) | GRM5 | |
| SCHEMBL20037762 | 0.70 | MAPT (0.43) | SLC22A12HDAC1HDAC8HDAC6NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100448848-C | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-01-07 | — | — | CN | claimed |
| EP-1757586-B1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | SERVIER LAB (FR) | 2008-12-03 | — | — | EP | claimed |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATORIES SERVIER (FR) | 2008-06-19 | — | — | US | claimed |
| US-7388022-B2 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-06-17 | — | — | US | claimed |
| EP-1757586-A1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | Les Laboratoires Servier (FR) | 2007-02-28 | — | — | EP | claimed |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | claimed |
| CN-1903844-A | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-31 | — | — | CN | claimed |
| CN-100448848-C | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-01-07 | — | — | CN | disclosed |
| EP-1757586-B1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | SERVIER LAB (FR) | 2008-12-03 | — | — | EP | disclosed |
| EP-1142872-B1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATORIES SERVIER (FR) | 2008-06-19 | — | — | US | disclosed |
| US-7388022-B2 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-06-17 | — | — | US | disclosed |
| EP-1757586-A1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | Les Laboratoires Servier (FR) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | disclosed |
| CN-1903844-A | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-31 | — | — | CN | disclosed |
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6645956-B1 | 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment | SHIONOGI & CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6620841-B1 | Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) | SHIONOGI & CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | SYK 3784/4885GRM5 4361/4885FPR2 3564/4885 |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | CHRNA1, CHRM1, CHRNA9 | SYK 4424/4885GRM5 214/4885FPR2 676/4885 |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | CHRM1, CHRM2, CHRM3 | SYK 4156/4885GRM5 92/4885FPR2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.